To tackle disease unmet needs the Molecular Microbiology and Biotechnology laboratory aims to develop new strategies of antibody engineering and synthetic biology for the advance of new biopharmaceuticals by interrogating the immune humoral and cellular responses in infectious diseases and biologic therapies.
Understand the immune response in infectious diseases and biologic therapies.
Our research interrogates how the antibody and cellular responses occur during Covid19 infection and vaccination, and during patient treatment with biologic therapies. We aim to determine what is the impact of immune profiling, dynamics, and depth of immunogenic outcomes for a successful control of infection and anti-drug antibody response.
Mimic nature with synthetic biology.
We aim to develop novel methodologies to generate genetic diversity directly into antibody genes using genome edition by CRISPR, TALE or zinc-finger nucleases and couple it with cellular display/selection. These technologies are explored together with synthetic biology to design novel genetic circuits into cell and phages and generate improved methods to discover therapeutic antibodies.
Integration of antibody engineering and synthetic biology for oncology and infectious diseases.
We are interested to integrate antibody engineering with synthetic biology to develop bispecific and multi-functional domain antibodies and conditional CAR-T cells. The boolean logic gates-based regulation of gene expression in CAR-T by conditional extracellular signals aims to improve pharmacologic activities in oncology and viral diseases, such as solid tumors and HIV-cure.